Amonafide: A future in treatment of resistant and secondary acute myeloid leukemia?

Expert Review of Hematology

Volumn 5, Issue 1, 2012, Pages 17-26

  Freeman, Ciara L ^a   Swords, Ronan ^b   Giles, Francis J ^c  

^a Department of Hematology and Oncology ^*  (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

AML; amonafide (l malate); cytarabine (ARA C); MDR proteins; multidrug resistance; N acetyltransferase 2 (NAT2); naphthalimides; P glycoprotein; secondary AML treatment related AML (sAML tAML); topoisomerase II inhibitor

Indexed keywords

AMONAFIDE; ANTHRACYCLINE; ANTILEUKEMIC AGENT; BILIRUBIN; CREATININE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; NAPHTHALIMIDE DERIVATIVE; ORPHAN DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ARTICLE; BACTEREMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER MODEL; CANCER SURVIVAL; CLINICAL LABORATORY; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CYTOGENETICS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; ERYTHEMA; HUMAN; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; LOADING DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MYELOBLAST; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEPTIC SHOCK; SOLID TUMOR; TINNITUS; VOMITING; BONE MARROW DEPRESSION; CARDIOTOXICITY; CONTINUOUS INFUSION; DESQUAMATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; LIVER METABOLISM; URINARY EXCRETION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NAPHTHALIMIDES; TOPOISOMERASE II INHIBITORS;

EID: 84856240667     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.68     Document Type: Article

References (73)

1. McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood 62(1), 1-13 (1983). (Pubitemid 13070585)
2. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 106(4), 1154-1163 (2005). (Pubitemid 41130866)
3. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 107(9), 2099-2107 (2006). (Pubitemid 44665642)
4. Erba HP. Prognostic factors in elderly patients with AML and the implications for treatment. Hematol. Am. Soc. Hematol. Educ. Program 420-428 (2007).
5. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J. Clin. 52(6), 363-371 (2002). (Pubitemid 35446607)
6. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J. Clin. 60(5), 277-300 (2010).
7. Chau M, Christensen JL, Ajami AM, Capizzi RL. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk. Res. 32(3), 465-473 (2008). (Pubitemid 351295924)
8. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 107(9), 3481-3485 (2006).
9. Appelbaum FR, Rosenblum D, Arceci RJ et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109(5), 1810-1816 (2007). (Pubitemid 46348174)
10. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council adult and children's leukaemia working parties. Blood 92(7), 2322-2333 (1998). (Pubitemid 28452973)
11. Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood 100(13), 4325-4336 (2002). (Pubitemid 35429670)
12. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96(13), 4075-4083 (2000).
13. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist. Updat. 12(3), 81-89 (2009).
14. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89(9), 3323-3329 (1997).
15. Leith CP, Kopecky KJ, Chen IM et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 94(3), 1086-1099 (1999). (Pubitemid 29361842)
16. Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group leukemia research program. Semin. Hematol. 34(4 Suppl. 5), S25-S33 (1997).
17. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 58(7), 931-959 (2001). (Pubitemid 32652819)
18. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. 64(14), 4927-4930 (2004). (Pubitemid 38924539)
19. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 22(47), 7537-7552 (2003). (Pubitemid 37487175)
20. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 453(5), 675-684 (2007). (Pubitemid 46192538)
21. Benderra Z, Faussat AM, Sayada L et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res. 10(23), 7896-7902 (2004). (Pubitemid 39587528)
22. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 63(2), 351-358 (2003). (Pubitemid 36158370)
23. Ikezoe T, Yang J, Nishioka C et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol. Cancer Ther. 6(6), 1851-1857 (2007). (Pubitemid 46954062)
24. De Jonge-Peeters SD, Kuipers F, De Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit. Rev. Oncol. Hematol. 62(3), 214-226 (2007). (Pubitemid 46679286)
25. Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood 100(4), 1224-1232 (2002). (Pubitemid 34864276)
26. Berman E, Heller G, Santorsa J et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77(8), 1666-1674 (1991).
27. Wiernik PH, Banks PL, Case DC Jr et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79(2), 313-319 (1992).
28. Vogler WR, Velez-Garcia E, Weiner RS et al. A Phase 3 trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J. Clin. Oncol. 10(7), 1103-1111 (1992).
29. Mandelli F, Petti MC, Ardia A et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur. J. Cancer 27(6), 750-755 (1991).
30. Arlin Z, Case DC Jr, Moore J et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 4(3), 177-183 (1990). (Pubitemid 20099889)
31. Hansen OP, Pedersen-Bjergaard J, Ellegaard J et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national Phase 3 trial. The Danish Society of Hematology study group on AML, Denmark. Leukemia 5(6), 510-516 (1991).
32. Buchner T, Hiddemann W, Schoch C, Haferlach T, Sauerland MC, Heinecke A. Acute myeloid leukaemia (AML): treatment of the older patient. Best Pract. Res. Clin. Haematol. 14(1), 139-151 (2001). (Pubitemid 32385150)
33. Rowe JM, Neuberg D, Friedenberg W et al. A Phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103(2), 479-485 (2004). (Pubitemid 38140076)
34. Lowenberg B, Suciu S, Archimbaud E et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-oncology Cooperative Hovon Group. J. Clin. Oncol. 16(3), 872-881 (1998). (Pubitemid 28115455)
35. Goldstone AH, Burnett AK, Wheatley K et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98(5), 1302-1311 (2001).
36. Anderson JE, Kopecky KJ, Willman CL et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 100(12), 3869-3876 (2002). (Pubitemid 35396851)
37. Bishop JF, Matthews JP, Young GA et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87(5), 1710-1717 (1996). (Pubitemid 26068888)
38. Weick JK, Kopecky KJ, Appelbaum FR et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88(8), 2841-2851 (1996). (Pubitemid 26357364)
39. Wolff SN, Herzig RH, Fay JW et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J. Clin. Oncol. 7(9), 1260-1267 (1989). (Pubitemid 19220127)
40. Bishop JF, Lowenthal RM, Joshua D et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 75(1), 27-32 (1990). (Pubitemid 20031485)
41. Estey EH, Thall PF, Cortes JE et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98(13), 3575-3583 (2001).
42. Fernandez HF, Sun Z, Yao X et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361(13), 1249-1259 (2009).
43. Lowenberg B, Ossenkoppele GJ, Van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361(13), 1235-1248 (2009).
44. Feldman EJ. Too much ara-C? Not enough daunorubicin? Blood 117(8), 2299-2300 (2011).
45. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. N. Engl. J. Med. 331(14), 896-903 (1994). (Pubitemid 24299870)
46. Baer MR. Clinical significance of multidrug resistance in AML: current insights. Clin. Adv. Hematol. Oncol. 3(12), 910-912 (2005). (Pubitemid 43168747)
47. Greenberg PL, Lee SJ, Advani R et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a Phase 3 trial (E2995). J. Clin. Oncol. 22(6), 1078-1086 (2004). (Pubitemid 41095041)
48. Leith CP, Chen IM, Kopecky KJ et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 86(6), 2329-2342 (1995).
49. Brana MF, Ramos A. Naphthalimides as anti-cancer agents: synthesis and biological activity. Curr. Med. Chem. Anticancer Agents 1(3), 237-255 (2001).
50. Capranico G, Binaschi M. DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta 1400(1-3), 185-194 (1998). (Pubitemid 28475103)
51. Liu Yin JA, Wheatley K, Rees JK, Burnett AK; UK MRC Adult Leukemia Working Party. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br. J. Haematol. 113(3), 713-726 (2001). (Pubitemid 32524396)
52. Cripe LD, Uno H, Paietta EM et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116(20), 4077-4085 (2010).
53. Chauncey TR, Gundacker H, Shadman M et al. Sequential Phase 2 Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br. J. Haematol. 148(1), 48-58 (2010).
54. Michieli M, Damiani D, Ermacora A et al. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br. J. Haematol. 106(1), 92-99 (1999). (Pubitemid 29343532)
55. Latagliata R, Breccia M, Fazi P et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br. J. Haematol. 143(5), 681-689 (2008).
56. Otake YCM, Ajami AM, Fernandes DJ. Amonafide interferes with topoisomerase II binding to DNA and induces chromatin disorganization. Proc. AACR 49, 152 (2008).
57. Hsiang YH, Jiang JB, Liu LF. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol. Pharmacol. 36(3), 371-376 (1989). (Pubitemid 19246761)
58. Felder TB, Mclean MA, Vestal ML et al. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug Metab. Dispos. 15(6), 773-778 (1987). (Pubitemid 18019768)
59. O'Brien S, Benvenuto JA, Estey E, Beran M, Felder TB, Keating M. Phase 1 clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res. 51(3), 935-938 (1991).
60. Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat. Res. 436(3), 227-261 (1999). (Pubitemid 29246091)
61. Ratain MJ, Mick R, Berezin F et al. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin. Pharmacol. Ther. 50(5Pt1), 573-579 (1991).
62. Ratain MJ, Rosner G, Allen SL et al. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J. Clin. Oncol. 13(3), 741-747 (1995).
63. Legha SS, Ring S, Raber M, Felder TB, Newman RA, Krakoff IH. Phase 1 clinical investigation of benzisoquinolinedione. Cancer Treat Rep. 71(12), 1165-1169 (1987).
64. Allen SL, Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, Budman DR. Phase 1 trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leuk. Res. 34(4), 487-491 (2010).
65. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51(2), 189-199 (1982). (Pubitemid 12073508)
66. Rizzieri DAEHP, O'Donnell M, Powell BL, Lundberg AS, Bennett JM, Capizzi RL. Amonafide + Ara-C in secondary acute myeloid leukemia (sAML): consistent efficacy in poor risk populations. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 7027).
67. Stone REA. A Phase 3, open-label, randomized comparison of AS1413 (amonafide l-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). J. Clin. Oncol. 29(Suppl.), (2011) (Abstract 6520).
68. Libby E, Hromas R. Dismounting the MDR horse. Blood 116(20), 4037-4038 (2010).
69. Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J. Clin. Oncol. 28(17), 2925-2935 (2010).
70. Robak T, Szmigielska-Kaplon A, Pluta A et al. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr. Med. Chem. 18(5), 638-666 (2011).
71. Moore JO, George SL, Dodge RK et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood 105(9), 3420-3427 (2005). (Pubitemid 40628181)
72. Tallman M. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia. Clin. Adv. Hematol. Oncol. 6(11), 3-5 (2008).
73. Dickson M, Gagnon JP. The cost of new drug discovery and development. Discov. Med. 4(22), 172-179 (2004).